RadiaDyne, the designer and manufacturer of the market leading Endorectal Balloon device utilized during radiation therapy for prostate cancer, announced today a pivotal published study utilizing their technology.
HOUSTON, July 31, 2018 /PRNewswire/ -- RadiaDyne, the designer and manufacturer of the market leading Endorectal Balloon device utilized during radiation therapy for prostate cancer, announced today a pivotal published study utilizing their technology. The study evaluated proton therapy to treat post-prostatectomy patients and demonstrated favorable late term patient outcomes through examination of associated post treatment toxicity profiles routinely reported for the procedure.
The study outlined acute and late term maximum GU and GI toxicities were predominantly grade 0 and 1. Grade 2 GU toxicities were less common, and no grade 3 toxicities were observed through a median 2-year follow up.
According to one of the authors from the study, Dr. Curtiland Deville, “this review is compelling as it is the first in the medical literature to report that proton therapy can be safely and effectively delivered for prostate cancer patients undergoing radiation in the post-operative setting. Previous studies have all reported on patients with an intact prostate. This study is important in that patterns of care have shifted over time with less routine screening for prostate cancer, more low risk patients being offered active surveillance, and more high-risk patients being offered surgery. These have all led to Radiation Oncologists now more often treating patients with adverse risk features in the post-prostatectomy setting. Thus, with my colleagues, we sought to treat and assess side effects and toxicity rates in prostate cancer patients requiring adjuvant or salvage radiation therapy using proton therapy. Patients in the study were treated using the RadiaDyne Endorectal balloon device to immobilize the prostatic fossa, provide reproducible anatomy, and spare the posterior rectal wall, which was critical to reduce dose uncertainties since protons have a finite range and no exit dose unlike photons. Our experience demonstrates that it is both feasible and safe to use proton therapy in the post-prostatectomy setting.”
About RadiaDyne
RadiaDyne is a privately held diagnostic and medical device company focused on patient dose monitoring and medical device technology to improve cancer treatment outcomes. RadiaDyne designs and innovates specialized sensor technology and medical treatment devices that assist Radiation Oncologists in delivering radiation dose to the cancerous targets while minimizing damage to the surrounding healthy tissue.
About RadiaDyne Endorectal Balloon
RadiaDyne’s legacy continues as the leader in radiation oncology immobilization balloon technology which provide solutions to reduce internal anatomical motion and stabilize targeted tissue for more accurate radiation dose to the cancerous target. Additionally, these balloon products displace healthy tissue out of the radiotherapy treatment area to minimize radiation exposure to healthy tissue. Please visit www.RadiaDyne.com to learn more.
To link to this article: https://doi.org/10.1080/0284186X.2018.1487583
View original content with multimedia:http://www.prnewswire.com/news-releases/radiadyne-announces-recently-published-clinical-article-studying-proton-therapy-for-post-prostatectomy-cancer-patients-utilizing-their-market-leading-endorectal-balloon-to-demonstrate-favorable-acute-and-late-gu-and-gi-toxicity-pr-300689236.html
SOURCE RadiaDyne
